Today, Nabi's new strategy took shape in the form of a merger with Australia's flu drug developer Biota, which is now moving its headquarters to the U.S.
Just a month after granting major contracts to VaxInnate and Novavax , BARDA is giving $231 million to Australia-based Biota for the company's flu treatment laninamivir. The drug is a long acting
Australia's Biota says a late-stage Asian trial of a new influenza therapy aimed at the blockbuster space occupied by Tamiflu delivered positive data, setting it up to begin commercialization as it
The world may be waiting for WHO to determine whether the swine flu outbreak is indeed a pandemic, but investors aren't waiting to place their money on "yes." Pharma stocks in general are on the
Boehringer Ingelheim must be happy with its previous partnership Â with Ablynx.
Coley Pharmaceutical of Wellesley, MA is shuttering its development program for the hepatitis C drug Actilon after a mid-stage trial failed to show any benefit in reducing viral load. Coley terminated 33 workers, or about a quarter of its staff, and announced that it is shifting gears in research to focus on RNA therapies that stimulate Toll-like receptors. The company is also outsourcing its drug discovery work. Altogether, Coley execs say the restructuring will save $15 …
Boehringer Ingelheim is teaming up with Germany's Ablynx to develop a "nanobody" program that targets Alzheimer's. The companies pegged the value of the worldwide licensing deal at a total of $265
Bayer sells H.C. Starck to investors for $1.57B
Australia's Biota has signed a $102 million pact to collaborate with Germany's Boehringer Ingelheim on a new therapy for Hepatitis C. The agreement covers Biota's nucleoside analogues product for hep C and other diseases. Biota gains immediate research support in the deal along with milestones and future royalties. Exact terms were not disclosed. - here's the report on the pact from The Age
The FDA has drafted new guidelines aimed at cutting the development process for new flu vaccines by one to two years. These guidelines outline the data that developers will need to provide to gain the agency's approval. The FDA has been pushing a variety of new measures aimed at speeding the development process. The change includes a fresh look at live virus treatments delivered through a nasal spray. The agency is particularly interested in fostering new technology for the speedier …